Home › Trials › NCT06058585

Investigating treatments for chronic kidney disease

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

PHASE3 · The George Institute · NCT06058585

This study is testing different treatments for chronic kidney disease to see which ones can help slow down the disease and prevent kidney failure.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment1000 (estimated)
Ages18 Years and up
SexAll
SponsorThe George Institute (other)
Locations43 sites (Garran, Australian Capital Territory and 42 other locations)
Trial IDNCT06058585 on ClinicalTrials.gov

What this trial studies

CAPTIVATE is an international, multi-centre, Phase III adaptive platform trial designed to identify the most effective treatments for chronic kidney disease (CKD). The trial aims to slow CKD progression and reduce the incidence of kidney failure by testing multiple treatments within a common framework. Participants will receive treatments for two years and will be monitored through regular follow-up visits to assess their health and treatment effects. The adaptive design allows for the addition of new treatments and the removal of ineffective ones, enhancing the efficiency of the research.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with chronic kidney disease and an eGFR of 25 mL/min/1.73m2 or higher.

Not a fit: Patients who are planning to start kidney replacement therapy or have a life expectancy of less than 6 months may not benefit from this study.

Why it matters

Potential benefit: If successful, this trial could lead to more effective treatments that significantly slow the progression of chronic kidney disease.

How similar studies have performed: Other studies have shown promise in using adaptive platform designs for chronic conditions, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age ≥ 18 years
2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
3. Currently receiving standard of care treatment according to treating physician
4. Eligible for randomisation in at least one recruiting domain-specific appendix
5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
2. Life expectancy less than 6 months

Where this trial is running

Garran, Australian Capital Territory and 42 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Chronic Kidney Diseases, Chronic kidney disease, Mineralocorticoid Receptor Antagonist, Finerenone

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.